Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 73 kDa 
• Atom Count: 4,717 
• Modelled Residue Count: 594 
• Deposited Residue Count: 636 
• Unique protein chains: 1

 5DG5

CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP-4157

• PDB DOI:  https://doi.org/10.2210/pdb5DG5/pdb

• Classification: TRANSFERASE/TRANSFERASE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2015-08-27 Released: 2016-08-31 
• Deposition Author(s): Smith, B.D., Kaufman, M.D., Leary, C.B., Turner, B.A., Wise, S.A., Ahn, Y.M., Booth, R.J., Caldwell, T.M., Ensinger, C.L., Hood, M.M., Lu, W.-P., Patt, T.W., Patt, W.C., Rutkoski, T.J., Samarakoon, T., Telikepalli, H., Vogeti, L., Vogeti, S., Yates, K.M., Chun, L., Stewart, L.J., Clare, M., Flynn, D.L.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.60 Å
• R-Value Free: 0.245 
• R-Value Work: 0.204 
• R-Value Observed: 0.206 

Literature

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.

Smith, B.D., Kaufman, M.D., Leary, C.B., Turner, B.A., Wise, S.C., Ahn, Y.M., Booth, R.J., Caldwell, T.M., Ensinger, C.L., Hood, M.M., Lu, W.P., Patt, T.W., Patt, W.C., Rutkoski, T.J., Samarakoon, T., Telikepalli, H., Vogeti, L., Vogeti, S., Yates, K.M., Chun, L., Stewart, L.J., Clare, M., Flynn, D.L.

(2015) Mol Cancer Ther 14: 2023-2034

• PubMed: 26285778 
• DOI: https://doi.org/10.1158/1535-7163.MCT-14-1105
• Primary Citation of Related Structures:  
  5DG5


• PubMed Abstract: 
  

Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases. This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations. Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo. Through its balanced inhibitory potency versus MET, TIE2, and VEGFR2, altiratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis. Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.

---

Organizational Affiliation: 

Deciphera Pharmaceuticals, Lawrence, Kansas. Deciphera Pharmaceuticals, Waltham, Massachusetts. [e-mail].

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Hepatocyte growth factor receptor	A, B	318	Homo sapiens	Mutation(s): 0  Gene Names: MET EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P08581 (Homo sapiens) Explore P08581  Go to UniProtKB:  P08581
PHAROS:  P08581

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
5B4	C [auth A], D [auth B]	N-(2,5-difluoro-4-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxam ide C26 H20 F3 N5 O3 YLLMKENFMVEIDG-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.60 Å
• R-Value Free: 0.245 
• R-Value Work: 0.204 
• R-Value Observed: 0.206 
• Space Group: P 1 2₁ 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 37.13	α = 90
b = 115.88	β = 92.92
c = 90.16	γ = 90

Software Package:

Software Name	Purpose
XDS	data reduction
XSCALE	data scaling
PHASER	phasing
Coot	model building
REFMAC	refinement

Structure Validation

Entry History 

Deposition Data

• Released Date: 2016-08-31 
Deposition Author(s): Smith, B.D., Kaufman, M.D., Leary, C.B., Turner, B.A., Wise, S.A., Ahn, Y.M., Booth, R.J., Caldwell, T.M., Ensinger, C.L., Hood, M.M., Lu, W.-P., Patt, T.W., Patt, W.C., Rutkoski, T.J., Samarakoon, T., Telikepalli, H., Vogeti, L., Vogeti, S., Yates, K.M., Chun, L., Stewart, L.J., Clare, M., Flynn, D.L.

Revision History  

• Version 1.0: 2016-08-31
  Type: Initial release